Teniposide (VM-26) as a single drug treatment for patients with extensive small cell lung carcinoma: A Phase II Study of the Southwest Oncology Group

Cancer

Volumn 80, Issue 6, 1997, Pages 1029-1033

  Grozea, Petre N ^a   Crowley, John J ^b,c   Canfield, Vikki A ^a   Kingsbury, Laura ^b,c   Ross, S William ^e   Beltran, German S ^f   Laufman, Leslie Rodgers ^g,h   Weiss, Geoffrey R ⁱ   Livingston, Robert B ^c,d  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b SW Oncology Group Statistical Center ^*  (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^f TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Department of Hematology Oncology   (United States)

^h Hematol/Oncology Consultants Inc   (United States)

ⁱ UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Cooperative group; Extensive small ceil lung carcinoma; Phase II study; Teniposide

Indexed keywords

TENIPOSIDE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; HYPONATREMIA; INTRAVENOUS DRUG ADMINISTRATION; LUNG SMALL CELL CANCER; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ACTUARIAL ANALYSIS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, SMALL CELL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TENIPOSIDE; TREATMENT OUTCOME;

EID: 0030772116     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970915)80:6<1029::AID-CNCR4>3.0.CO;2-4     Document Type: Article

References (22)

1. Seiffer EJ, Ihde DC. Therapy of small cell lung cancer: a perspective of two decades of clinical research. Semin Oncol 1988;15:278-99.
2. Johnson DH, Hainsworth JD, Hande KR, Greco FA. Current status of etoposide in the management of small cell lung cancer. Cancer 1991;67(Suppl):231-44.
3. O'Dwyer PJ, Alonso MT, Leyland-Jones B, Marsoni S. Teniposide: a review of 12 years of experience. Cancer Treat Rep 1984;68:1445-66.
4. Current perspectives on teniposide (VM-26): an international conference. Semin Oncol 1992;19(Suppl 6):1-94.
5. Aisner J. Identification of new drugs in small cell lung cancer: Phase II agents first? Cancer Treat Rep 1987;71:1131-3.
6. Aisner J. Strategies for new drug identification in small cell lung cancer. Proceedings of the satellite symposium on current perspectives in the treatment of small cell lung cancer, Melbourne, Australia, November 10, 1991. Lung Cancer 1993;9(Suppl 1):S99-S107.
7. Ettinger DS. Evaluation of new drugs in untreated patients with small cell lung cancer: its time has come. J Clin Oncol 1990;8:374-7.
8. Ettinger DS. Justification for evaluating new anticancer drugs in selected untreated patients with extensive stage small-cell lung cancer: an Eastern Cooperative Oncology Group randomized study. J Natl Cancer Inst 1992;84:1077-84.
9. Giaccone G, Donadio M, Bonardi M, Testore F, Calciati A. Teniposide in the treatment of small cell lung cancer: the influence of prior chemotherapy. J Clin Oncol 1988;6:1264-70.
10. Giaccone G. Identification of new drugs in pretreated patients with small cell lung cancer. Eur J Cancer Clin Oncol 1989;25:411-3.
11. Grant SC, Gralla RJ, Kris MG, Orazem J, Kitsis EA. Single agent chemotherapy trials in small cell lung cancer, 1970-1990: the case for studies in previously treated patients. J Clin Oncol 1992;10:484-98.
12. Cullen M. The design of phase II trials. Third IASLC workshop on small lung cancer, Elsinore, Denmark, 18-22 June 1989. Lung Cancer 1989;5:214-20.
13. Samson MK, Baker LH, Talley RW, Fraile RJ. VM-26 (NCS 122819): a clinical study in advanced cancer of the lung and ovary. Eur J Cancer 1978;14:1395-9.
14. Woods RL, Fox RM, Tattersall MHN. Treatment of small cell lung bronchogenic carcinoma with VM-26. Cancer Treat Rep 1979;63:2011-3.
15. Spremulli E, Schultz JJ, Speckhart VJ, Wampler GL. Phase II study of VM-26 in adult malignancies. Cancer Treat Rep 1980;64:147-9.
16. Pedersen AG, Bork E, Osterlind K, Dombernowsky P, Hansen HH. Brief report: phase II study of teniposide in small cell carcinoma of the lung. Cancer Treat Rep 1984;68:1289-91.
17. Bork E, Hansen M, Dombernowsky P, Hansen SW, Pedersen AG, Hansen HH. Teniposide (VM-26) an overlooked highly active agent in small cell lung cancer: results of a phase II trial in untreated patients. J Clin Oncol 1986;4:524-7.
18. Bork E, Ersboll J, Dombernowsky P, Bergman B, Hansen M, Hansen HH. Teniposide and etoposide in previously untreated small cell lung cancer: a randomized study. J Clin Oncol 1991;9:1627-31.
19. Bork E, Hansen M, Dombernowsky P, Hansen SW, Pedersen AG, Hansen HH, et al. VM-26, teniposide: the most active single agent in small cell lung cancer. Fourth World Conference on Lung Cancer, Toronto, Canada, August 25-30, 1985. Conference program and abstracts, Abstract #561, page 141.
20. Holoye PY, Winn RJ, Craig K, Goodwin W, Camnon MW. Phase II study of teniposide in small cell bronchogenic carcinoma. Proceedings of the American Society of Clinical Oncology, March 1989. Volume 8, Abstract #946, page 243.
21. Cerny T, Pedrazzini A, Joss RA, Bruner KW. Unexpected high toxicity in a phase II study of teniposide (VM-26) in elderly patients with untreated small cell lung cancer (SCLC). Eur J Cancer Clin Oncol 1988;24:1791-4.
22. Tummarello D, Isidori P, Pasini F, Cetto G, Cellerino R. Teniposide as single drug therapy for elderly patients affected by small cell lung cancer. Eur J Cancer 1992;28A:1081-4.